Ideal patients needed for initial implantations of Kamra inlay

Surgical correction of presbyopia was previously limited to procedures producing a monovision result, in which one eye is corrected for near vision and the other for far. Although effective, the asymmetric vision produced by monovision is not an ideal solution for many. In April 2015, the FDA approved the use of the Kamra corneal inlay from AcuFocus. The inlay is 3.8 mm in diameter with a 1.6 mm central opening that functions on the pinhole principle, much like a camera F-stop. The central aperture enables light to move directly from the cornea to the retina, extending the natural range of vision.With 81.5 million people between the ages of 45 years and 64 years in the United States, all of whom will experience presbyopia, the market reach of the Kamra inlay is in unprecedented territory. The Kamra inlay is the “first kid on the block,” much like LASIK when introduced in the U.S. during the late 1990s.